top of page

Ixazomib

MECHANISM OF ACTION

MECHANISM OF KIDNEY INJURY

CLINICAL KIDNEY SYNDROME

CARDIOVASCULAR ADVERSE EFFECTS

LYTE ABNORMALITIES

RISK FACTORS

MITIGATION STRATEGIES

SUGGESTIONS 

NOTES/COMMENTS

PHARMACOKINETICS

Molecular Weight

Volume of Distribution

Plasma Protein Binding

Metabolism

Bioavailability

Half-life elimination

Time to peak

Excretion

Dialyzable?

REF:

PATHOLOGY SLIDES:

ENTRY UPDATES:

Nov 7, 2024

bottom of page